Skip to content
OpenCapital
Get started

Organon OGN Acquired in-process research and development

Acquired in-process research and development at other companies

Biogen logo
BiogenBIIB
$35M—
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$228.9M+1.6%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's acquired in-process research and development?
Organon (OGN) reported acquired in-process research and development of $10M in Q1 2026.
How has Organon's acquired in-process research and development changed year-over-year?
Organon's acquired in-process research and development decreased by 0.0% year-over-year, from $10M to $10M.
What is the long-term trend for Organon's acquired in-process research and development?
Over 2 years (2021 to 2024), Organon's acquired in-process research and development has grown at a -17.4% compound annual growth rate (CAGR), from $104M to $71M.
What does acquired in-process research and development mean?
Represents the actual cash outflow for the acquisition of in-process research and development projects, typically in the pharmaceutical or biotechnology sectors. This metric serves as a proxy for the company's investment in future growth engines and its reliance on external R&D to replenish its product portfolio. It is a key indicator of the capital intensity required to maintain a competitive pipeline.